Skip to content
value.today

Aegle Therapeutics Corp

🇺🇸 Woburn, Massachusetts, USABiotechnologyFounded 2019
Total raised
$9 M
2 rounds on record
Latest round
$2 M
Aug 2026
First round on record
Jan 2020
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aegle Therapeutics Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$2 MNo. 2$2 to $10 million

Aegle Therapeutics Corp: Raise no. 2, Aug 2026

Investors in this round

17 investors had bought by the notice of Aug 28, 2026: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shelley Hartman · Executive Officer, Director
  • Evangelos Badiavas · Director
  • Leon Moulder · Director
  • Scott Braunstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shelley Hartman, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 28, 2026. Read the notice at the SEC.

equitySEC
Jan 2020$7 MNo. 1$2 to $10 million

Aegle Therapeutics Corp: Raise no. 1, Jan 2020

Investors in this round

8 investors had bought by the notice of Jul 28, 2020: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Evangelos Badiavas · Executive Officer, Director
  • Robert Williamson, Jr. · Executive Officer, Director
  • Shelley Hartman · Executive Officer, Director
  • David Schimel · Director
  • Elona Baum · Director
  • Leon Moulder, Jr. · Director
  • Robert Ryan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shelley Hartman, Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Jul 28, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aegle Therapeutics Corp chose not to state its revenue in its newest notice of a funding round (Aug 2026).

    SEC Form D · Aug 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2026

That is all the official record says: Aegle Therapeutics Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Aegle Therapeutics Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aegle Therapeutics Corp
NameRoleNamed in
Shelley HartmanExecutive officerAug 2026
Evangelos BadiavasExecutive officerJul 2020
Robert Williamson, Jr.Executive officerJul 2020
Evangelos BadiavasDirectorAug 2026
Leon MoulderDirectorAug 2026
Scott BraunsteinDirectorAug 2026
Shelley HartmanDirectorAug 2026
David SchimelDirectorJul 2020
Elona BaumDirectorJul 2020
Leon Moulder, Jr.DirectorJul 2020
Robert RyanDirectorJul 2020
Robert Williamson, Jr.DirectorJul 2020